Drug firm Nectar Lifesciences disclosed 16.38 per cent fall in standalone net profit to Rs 12.30 crore for the first quarter ended June 30, 2016-17. It had recorded net profit of Rs 14.71 crore for the same period of the last financial, according to the company. The Standalone total income from operations of the company is observed at Rs 354.43 crore for the quarter under consideration as compared to Rs 407.70 crore for the corresponding period year ago.
The not so fruitful Q1 did not have much impact on the Nectar Lifesciences share price which went up marginally by 0.58%. The stock opened at Rs. 34.05 against its previous closing at Rs. 34.50. The stock touched the day’s high and low at Rs. 35.30 and Rs.34.05. As of now 3,44,970 shares are traded in the counter as per NSE. The stock saw a spurt in volume on two consecutive days i.e on 23rd and 24th August by more than 2.72 times and 1.57 times respectively.
Nectar Lifesciences Limited is a renowned pharmaceutical company in India that produces generic products for EU and USA. The company is the biggest GMP manufacturer of oral and sterile cephalosporins in the world. Its facilities are approved by USFDA, the European Union and Japan.
The 52 week high of Nectar Lifesciences is seen at Rs. 60.90 on 8th Dec ’15 while the 52 week low is observed at Rs. 32 on 29thFeb ‘16. The Average Daily Movement of the stock is 2.10 and its average volume for last 20 days is 254076. The stock yields -7.25% monthly returns and has the PE ratio of13.09. The market cap of the company amounts to Rs. 773.70 (Cr)and has a book value of Rs. 45.36.
For further details on the support and resistance refer to Nectar Lifesciences share price forecast.
No comments:
Post a Comment